ArticleCurrent hepatitis reports2011
Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B.
Article in Current hepatitis reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Spatially structured models of viral dynamics: a scoping review.Microbiology and molecular biology reviews : MMBR · 2025Article
- Intracellular "In Silico Microscopes"-Comprehensive 3D Spatio-Temporal Virus Replication Model Simulations.Viruses · 2024Article
- Modeling-Based Response-Guided DAA Therapy for Chronic Hepatitis C to Identify Individuals for Shortening Treatment Duration.Open forum infectious diseases · 2022Article
- Machine learning for mathematical models of HCV kinetics during antiviral therapy.Mathematical biosciences · 2022Article
- Article
- High Cure Rates for Hepatitis C Virus Genotype 6 in Advanced Liver Fibrosis With 12 Weeks Sofosbuvir and Daclatasvir: The Vietnam SEARCH Study.Open forum infectious diseases · 2021Article
- Article
- Response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients: a Pilot study.Scientific reports · 2020Article
- Modeling based response guided therapy in subjects with recent hepatitis C infection.Antiviral research · 2020Article
- HCVMultiscaleFit: A Simulator For Parameter Estimation in Multiscale Models Of Hepatitis C Virus Dynamics.AIP conference proceedings · 2020Article
- A Parameter Estimation Method for Multiscale Models of Hepatitis C Virus Dynamics.Bulletin of mathematical biology · 2019Article
- Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis.Liver international : official journal of the International Association for the Study of the Liver · 2019Article
- Advanced Hepatitis C Virus Replication PDE Models within a Realistic Intracellular Geometric Environment.International journal of environmental research and public health · 2019Article
- Numerical schemes for solving and optimizing multiscale models with age of hepatitis C virus dynamics.Mathematical biosciences · 2018Article
- A New Model for the Dynamics of Hepatitis C Infection: Derivation, Analysis and Implications.Viruses · 2018Review
- Integrated pharmacokinetic/viral dynamic model for daclatasvir/asunaprevir in treatment of patients with genotype 1 chronic hepatitis C.Acta pharmacologica Sinica · 2018Article
- A Robust and Efficient Numerical Method for RNA-Mediated Viral Dynamics.Frontiers in applied mathematics and statistics · 2017Article
- 3D Spatially Resolved Models of the Intracellular Dynamics of the Hepatitis C Genome Replication Cycle.Viruses · 2017Article
- In-host modeling.Infectious Disease Modelling · 2017Article
- Resurrection of response-guided therapy for sofosbuvir combination therapies.Journal of hepatology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
In the last decade hepatitis C virus (HCV) kinetics has become an important clinical tool for the optimization of therapy with (pegylated)-interferon-α (IFN) and ribavirin (RBV). Mathematical models have generated important insights into HCV pathogenesis, HCV- host dynamics, and IFN and RBV's modes of action. Clinical trials with direct acting agents (DAAs) against various steps of the HCV life cycle have revealed new viral kinetic patterns that have not been observed with IFN±RBV. Very recently, studies have showed that single nucleotide polymorphisms (SNPs) in the IL28B gene region were associated with race/ethnicity and with response to IFN±RBV. Here we review our current knowledge of HCV kinetics and related mathematical models during IFN±RBV and/or DAA based therapies, HCV pathogenesis, and the role of IL28B polymorphism on early HCV kinetics. Better understanding of the mode of actions of drug(s) and viral kinetics may help to develop, in the near future, new individualized therapeutic regimens that include DAAs in combination with IFN+RBV.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.